Improvement of microscopic MR imaging of amyloid plaques with targeting and non-targeting contrast agents

Current Medical Imaging Reviews

Volumn 7, Issue 1, 2011, Pages 8-15

  Petiet, Alexandra ^a,b,c   Dhenain, Marc ^a,b,c  

^a CNRS   (France)

^b INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

^c CEA SACLAY   (France)

Author keywords

Alzheimer; Amyloid plaques; Contrast agent; Gadolinium; MRI; Passive staining

Indexed keywords

AMYLOID BETA PROTEIN; DYSPROSIUM; GADOBUTROL; GADODIAMIDE; GADOLINIUM; GADOLINIUM PENTETATE; GADOTERATE MEGLUMINE; GADOTERIDOL; GADOVERSETAMIDE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ARTICLE; BLOOD BRAIN BARRIER; CONTRAST ENHANCEMENT; CORPUS CALLOSUM; DIFFUSION TENSOR IMAGING; HIPPOCAMPUS; HUMAN; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHARMACOPHORE; PRIORITY JOURNAL; RADIOBIOLOGY; SIGNAL NOISE RATIO; STAINING;

EID: 79955647630     PISSN: 15734056     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340511794653496     Document Type: Article

References (61)

1. Jack CR, Jr, Lowe VJ, Weigand SD, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 2009; 132: 1355-65
2. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease:progress and problems on the road to therapeutics. Science 2002; 297: 353-6
3. Valk J, Barkhof F, Scheltens P. Magnetic resonance in dementia.2002, Heidelberg Berlin New York: Springer-Verlag. 353
4. Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet 2006; 368: 387-403
5. Nordberg A. Amyloid imaging in Alzheimer's disease. Curr Opin Neurol 2007; 20: 398-402
6. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004; 55: 306-19
7. Choi SR, Golding G, Zhuang Z, et al. Preclinical properties of 18FAV-45: a PET agent for Abeta plaques in the brain. J Nucl Med 2009; 50: 1887-94
8. Klunk WE, Lopresti BJ, Ikonomovic MD, et al. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. J Neurosci 2005; 25: 10598-606
9. Kuntner C, Kesner AL, Bauer M, et al. Limitations of small animal PET imaging with [18F]FDDNP and FDG for quantitative studies in a transgenic mouse model of Alzheimer's disease. Mol ImagingBiol 2009; 11: 236-40
10. Benveniste H, Einstein G, Kim KR, Hulette C, Johnson GA. Detection of neuritic plaques in Alzheimer's disease by magnetic resonance microscopy. Proc Natl Acad Sci USA 1999; 96: 14079-84
11. Dhenain M, Privat N, Duyckaerts C, Jacobs RE. Senile plaques donot induce susceptibility effects in T2*-weighted MR microscopic images. NMR Biomed 2002; 15: 197-203
12. Van Rooden S, Maat-Schieman ML, Nabuurs RJ, et al. Cerebral Amyloidosis: Postmortem Detection with Human 7.0-T MR ImagingSystem. Radiology 2009; 253: 788-96
13. Nakada T, Matsuzawa H, Igarashi H, Fujii Y, Kwee IL. In vivo visualization of senile-plaque-like pathology in Alzheimer's disease patients by MR microscopy on a 7T system. J Neuroimaging 2008;18: 125-9
14. Meadowcroft MD, Connor JR, Smith MB, Yang QX. MRI andhistological analysis of beta-amyloid plaques in both human Alzheimer's disease and APP/PS1 transgenic mice. J Magn Reson Imaging 2009; 29: 997-1007
15. Lee SP, Falangola MF, Nixon RA, Duff K, Helpern JA. Visualizationof beta-Amyloid plaques in a transgenic mouse model of Alzheimer'sdisease using MR microscopy without contrast reagents. Magn Reson Med 2004; 52: 538-44
16. Jack CR, Jr, Garwood M, Wengenack TM, et al. In vivo visualizationof Alzheimer's amyloid plaques by magnetic resonance imagingin transgenic mice without a contrast agent. Magn Reson Med 2004; 52: 1263-71
17. Jack CR, Jr, Wengenack TM, Reyes DA, et al. In vivo magneticresonance microimaging of individual amyloid plaques in Alzheimer'stransgenic mice. J Neurosci 2005; 25: 10041-8
18. Braakman N, Matysik J, van Duinen SG, et al. Longitudinal assessmentof Alzheimer's beta-amyloid plaque development intransgenic mice monitored by in vivo magnetic resonance microimaging. J Magn Reson Imaging 2006: 530-6
19. Chamberlain R, Reyes D, Curran GL, et al. Comparison of amyloidplaque contrast generated by T2-weighted, T2*-weighted, and susceptibility-weighted imaging methods in transgenic mouse modelsof Alzheimer's disease. Magn Reson Med 2009; 61: 1158-64
20. Dhenain M, El Tannir El Tayara N, Wu T-D, et al. Characterizationof in vivo MRI detectable thalamic amyloid plaques fromAPP/PS1 mice. Neurobiol Aging 2009; 30: 41-53
21. Vanhoutte G, Dewachter I, Borghgraef P, Van Leuven F, Van derLinden A. Noninvasive in vivo MRI detection of neuritic plaquesassociated with iron in APP[V717I] transgenic mice, a model forAlzheimer's disease. Magn Reson Med 2005; 53: 607-13
22. Faber C, Zahneisen B, Tippmann F, Schroeder A, Fahrenholz F. Gradient-echo and CRAZED imaging for minute detection of Alzheimerplaques in an APP(V717I) x ADAM10-dn mouse model. Magn Reson Med 2007; 57: 696-703
23. El Tannir El, Tayara N, Volk A, Dhenain M, Delatour B. Transverserelaxation time reflects brain amyloidosis in young APP/PS1transgenic mice. Magn Reson Med 2007; 58: 179-84
24. Roberts TP, Mikulis D., Neuro MR: principles. J Magn Reson Imaging 2007; 26: 823-37
25. Sobol WT. Magnetic resonance contrast agents. Physical basis ofrelaxation. Neuroimaging Clin N Am 1994; 4: 27-42
26. Bloembergen N. Proton relaxation times in paramagnetic solutions.J. Chem. Phys. 1957; 27: 572-73
27. Bloembergen N, Morgan LO. Proton relaxation times in paramagneticsolutions. effects of electron spin relaxation. J Chem Phys 1961; 34: 842-50
28. Solomon I. Relaxation processes in a system of two spins. Phys Rev 1955; 99: 559-565
29. Botta M. Second coordination sphere water molecules and relaxivityof gadolinium(III) complexes: implications for MRI contrastagents. Eur J Inorg Chem 2000: 399-407
30. Mendonça-Dias MH, Gaggelli E, Lauterbur PC. Paramagneticcontrast agents in nuclear magnetic resonance medical imaging. Sem Nucl Med 1983; 13: 364-76
31. Caravan P, Ellison JJ, McMurry TJ, Lauffer RB. Gadolinium(III)chelates as MRI contrast agents: structure, dynamics, and applications. Chem Rev 1999; 99: 2293-352
32. Vander Elst L, Roch A, Gillis P, et al. Dy-DTPA derivatives asrelaxation agents for very high field MRI: the beneficial effect ofslow water exchange on the transverse relaxivities. Magn ResonMed 2002; 47: 1121-30
33. Wang YX, Hussain SM, Krestin GP. Superparamagnetic iron oxidecontrast agents: physicochemical characteristics and applications in MR imaging. Eur Radiol 2001; 11: 2319-31
34. th Scientific Meeting, InternationalSociety for Magnetic Resonance in Medicine. 2009. Honolulu:1090
35. Wadghiri YZ, Sigurdsson EM, Wisniewski T, Turnbull DH. Magneticresonance imaging of amyloid plaques in transgenic mice. Methods Mol Biol 2005; 299: 365-79
36. Sigurdsson EM, Wadghiri YZ, Mosconi L, et al. A non-toxicligand for voxel-based MRI analysis of plaques in AD transgenicmice. Neurobiol Aging 2008; 29: 836-47
37. Ramakrishnan M, Wengenack TM, Kandimalla KK, et al. SelectiveContrast Enhancement of Individual Alzheimer's Disease AmyloidPlaques Using a Polyamine and Gd-DOTA Conjugated AntibodyFragment Against Fibrillar Abeta42 for Magnetic Resonance MolecularImaging. Pharm Res 2008; 25(8): 1861-72
38. Poduslo JF, Wengenack TM, Curran GL, et al. Molecular targetingof Alzheimer's amyloid plaques for contrast-enhanced magneticresonance imaging. Neurobiol Dis 2002; 11: 315-29
39. Zaim Wadghiri Y, Sigurdsson EM, Sadowski M, et al. Detection ofAlzheimer's amyloid in transgenic mice using magnetic resonancemicroimaging. Magn Reson Med 2003; 50: 293-302
40. Wadghiri Y, Douadi M, Wisniewski T, Yang J, Utku Y, Kirshenbaum K. Targeting Alzheimer's plaques with Dysprosium based probes. in Proceedings 16 Scientific Meeting, International Society for Magnetic Resonance in Medicine. 2008. Toronto: 255
41. Maggio JE, Stimson ER, Ghilardi JR, et al. Reversible in vitrogrowth of Alzheimer disease beta-amyloid plaques by deposition of labeled amyloid peptide. Proc Natl Acad Sci USA 1992; 89: 5462-6
42. Trouche SG, Asuni A, Rouland S, et al. Antibody response and plasma Abeta1-40 levels in young Microcebus murinus primatesimmunized with Abeta1-42 and its derivatives. Vaccine 2009; 27:957-64
43. Poduslo JF, Ramakrishnan M, Holasek SS, et al. In vivo targeting of antibody fragments to the nervous system for Alzheimer's disease immunotherapy and molecular imaging of amyloid plaques. J Neurochem 2007; 102: 420-33
44. Poduslo JF, Curran GL. Polyamine modification increases the permeability of proteins at the blood-nerve and blood-brain barriers. J Neurochem 1996; 66: 1599-609
45. Choi JJ, Pernot M, Small SA, Konofagou EE. Noninvasive, transcranial and localized opening of the blood-brain barrier using focused ultrasound in mice. Ultrasound Med Biol 2007; 33: 95-104
46. Raymond SB, Treat LH, Dewey JD, McDannold NJ, Hynynen K, Bacskai BJ. Ultrasound enhanced delivery of molecular imagingand therapeutic agents in Alzheimer's disease mouse models. PLoS One 2008; 3: e2175
47. th Scientific Meeting, International Society for Magnetic Resonance in Medicine 2008. Toronto: 2306
48. Bing KF, Howles GP, Qi Y, Palmeri ML, Nightingale KR. Bloodbrain barrier (BBB) disruption using a diagnostic ultrasound scanner and definity in mice. Ultrasound Med Biol 2009; 35: 1298-308
49. Abbott NJ, Romero IA. Transporting therapeutics across the bloodbrain barrier. Mol Med Today 1996; 2: 106-13
50. Abbott NJ, Ronnback L, Hansson E. Astrocyte-endothelial interactionsat the blood-brain barrier. Nat Rev Neurosci 2006; 7: 41-53
51. Johnson GA, Cofer GP, Gewalt SL, Hedlund LW. Morphologic phenotyping with MR microscopy: The visible mouse. Radiology 2002; 222: 789-93
52. Dhenain M, Delatour B, Walczak C, Volk A. Passive staining: Anovel ex vivo MRI protocol to detect amyloid deposits in mouse models of Alzheimer's disease. Magn Reson Med 2006; 55: 687-93
53. Kappeler C, Dhenain M, Phan Dinh Tuy F, et al. MRI and histological studies of corpus callosal and hippocampal abnormalities linked to doublecortin deficiency. J Comp Neurol 2007; 500: 239-54
54. Johnson GA, Cofer GP, Fubara B, Gewalt SL, Hedlund LW, Maronpot RR. Magnetic resonance histology for morphologic phenotyping. J Magn Reson Imaging 2002; 16: 423-9
55. Benveniste H, Kim K, Zhang L, Johnson GA. Magnetic resonancemicroscopy of the C57BL mouse brain. NeuroImage 2000; 11:601-11
56. Petiet A, Hedlund L, Johnson GA. Staining methods for magnetic resonance microscopy of the rat fetus. J Magn Reson Imaging 2007; 25: 1192-8
57. Petiet AE, Kaufman MH, Goddeeris MM, Brandenburg J, Elmore SA, Johnson GA. High-resolution magnetic resonance histology of the embryonic and neonatal mouse: a 4D atlas and morphologic database. Proc Natl Acad Sci USA 2008; 105: 12331-6
58. Johnson GA, Ali-Sharief A, Badea A, et al. High-throughput morphologic phenotyping of the mouse brain with magnetic resonance histology. Neuroimage 2007; 37: 82-9
59. D'Arceuil HE, Westmoreland S, de Crespigny AJ. An approach to high resolution diffusion tensor imaging in fixed primate brain. Neuroimage 2007; 35: 553-65
60. D'Arceuil H, Liu C, Levitt P, Thompson B, Kosofsky B, de Crespigny A. Three-dimensional high-resolution diffusion tensor imagingand tractography of the developing rabbit brain. Dev Neurosci 2008; 30: 262-75
61. Tweedle MF, Wedeking P, Kumar K. Biodistribution of radiolabeled, formulated gadopentetate, gadoteridol, gadoterate, andgadodiamide in mice and rats. Invest Radiol 1995; 30: 372-80.